What we’re reading, December 20, 2016: Purdue Pharma, which makes OxyContin, plans to expand its sales of the drug in foreign markets; family members blame hospital for not warning them about low-quality nursing home; a project to place blast sensors on soldiers to learn more about concussions has been discontinued.
The Los Angeles Times reports that Purdue Pharma, the manufacturer of OxyContin, is pursuing a new business strategy to boost sales of the opioid drug in overseas markets including South America, Asia, and Africa. Tactics include seminars designed to reduce “opiophobia,” or doctors’ aversion to prescribing narcotics. According to the investigation, the use of promotional materials that downplay the risk of addiction is reminiscent of “the initial marketing of OxyContin in the US in the late 1990s when Purdue deceived doctors about the drug’s addictiveness.”
Upon a patient’s discharge from a hospital for hip surgery, family members say they were pushed to choose that hospital’s affiliated nursing home, where the patient later died from allegedly neglectful care. According to Kaiser Health News, the hospital failed to warn them that the nursing home had a CMS quality rating of just 1 star, and that the facility had been fined multiple times for insufficient care. Meanwhile, a federal rule that would require hospitals to provide guidance and quality data on nursing homes and other post-discharge facilities has stalled in Congress.
The Pentagon has abandoned an initiative that placed blast sensors on soldiers to gauge pressure caused by an explosion. NPR reports that “the monitoring was discontinued because the gauges failed to reliably show whether service members had been close enough to an explosion to have sustained a concussion, or mild traumatic brain injury.” Before the sensors were retired, data from them suggested that soldiers were commonly exposed to overpressure when firing heavy weapons like recoilless rifles.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Innovation in Value-Based Care Requires More Data, Patient-Centered Thinking
November 9th 2023In a panel discussion at the 2023 Patient-Centered Oncology Care® meeting held in Nashville, Tennessee, experts discussed the Enhancing Oncology Model and themes in the movement toward value-based care in oncology.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
EOM Shows Awareness of Issues, but Provides No Resources, Says COA’s Nicolas Ferreyros
November 4th 2023The Enhancing Oncology Model is trying to address a number of the systemic challenges oncology faces without giving practices the tools and resources they need, said Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.
Read More